Tonix Pharmaceuticals Targets TONMYA Growth as Lyme Prevention Trial Nears
Published . Updated .
Pharma Frenzy: Volatility Ignites Biotech SectorTonix Pharmaceuticals (NASDAQ:TNXP) CEO Seth Lederman told attendees at the Cantor Healthcare Conference that the company’s near-term focus is the commercial launch of TONMYA, its FDA-approved treatment for fibromyalgia in adults, w
Directly affected
- NDAQ Nasdaq
Named in this report.
Indirectly affected
- XLV Health Care Select Sector SPDR
A fund of health-care companies
- XBI SPDR S&P Biotech
A fund of biotechnology companies
- UNH UnitedHealth
A large health insurer
- JNJ Johnson & Johnson
A large health-care company
- LLY Eli Lilly
A large drug maker
- PFE Pfizer
A large drug maker
- ACHC ACADIA HEALTHCARE COMPANY INC
GA selected ACHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- ASND ASCENDIS PHARMA A/S
GA selected ASND as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- ATYR ATYR PHARMA INC COM NEW
GA selected ATYR as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- BBIO BRIDGEBIO PHARMA INC
GA selected BBIO as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
Price reaction, T-5 to T+3
Pharma Frenzy: Volatility Ignites Biotech SectorTonix Pharmaceuticals (NASDAQ:TNXP) CEO Seth Lederman told attendees at the Cantor Healthcare Conference that the company’s near-term focus is the commercial launch of TONMYA, its FDA-approve…
Source: Nasdaq Markets
How far Acadia Healthcare (ACHC) has moved since 13 Sep 2026
Since the first closing price after “Tonix Pharmaceuticals Targets TONMYA Growth as Lyme Prevention Trial Nears,” Acadia Healthcare (ACHC) is +7.90%. The S&P 500 fund (SPY) is +0.77% over the same days, a +7.13% difference versus the market.
Disclosure records for Acadia Healthcare (ACHC) within two months of 13 Sep 2026
- Gilbert Cisneros sell BridgeBio Pharma (BBIO) ($1,001 - $15,000). That is 16 days after publication, inside 30 days. The filing is listed beside the story “Tonix Pharmaceuticals Targets TONMYA Growth as Lyme Prevention Trial Nears.”
- Rohit Khanna buy GE HealthCare Technologies (GEHC) ($1,001 - $15,000). That is 2 days before publication, inside 30 days. The filing is listed beside the story “Tonix Pharmaceuticals Targets TONMYA Growth as Lyme Prevention Trial Nears.”
- Rohit Khanna buy GE HealthCare Technologies (GEHC) ($1,001 - $15,000). That is 41 days before publication, inside 60 days. The filing is listed beside the story “Tonix Pharmaceuticals Targets TONMYA Growth as Lyme Prevention Trial Nears.”
- Rohit Khanna buy GE HealthCare Technologies (GEHC) ($1,001 - $15,000). That is 45 days before publication, inside 60 days. The filing is listed beside the story “Tonix Pharmaceuticals Targets TONMYA Growth as Lyme Prevention Trial Nears.”
- Rohit Khanna buy GE HealthCare Technologies (GEHC) ($1,001 - $15,000). That is 45 days before publication, inside 60 days. The filing is listed beside the story “Tonix Pharmaceuticals Targets TONMYA Growth as Lyme Prevention Trial Nears.”
- Rohit Khanna buy GE HealthCare Technologies (GEHC) ($1,001 - $15,000). That is 52 days before publication, inside 60 days. The filing is listed beside the story “Tonix Pharmaceuticals Targets TONMYA Growth as Lyme Prevention Trial Nears.”
- Rohit Khanna buy GE HealthCare Technologies (GEHC) ($1,001 - $15,000). That is 54 days before publication, inside 60 days. The filing is listed beside the story “Tonix Pharmaceuticals Targets TONMYA Growth as Lyme Prevention Trial Nears.”
- Donald J Trump sell GE HealthCare Technologies (GEHC) ($1,001 - $15,000). That is 58 days before publication, inside 60 days. The filing is listed beside the story “Tonix Pharmaceuticals Targets TONMYA Growth as Lyme Prevention Trial Nears.”
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
Who gains and who loses around Acadia Healthcare (ACHC)
Companies tied to this story
- ACHC Acadia Healthcare
In “Tonix Pharmaceuticals Targets TONMYA Growth as Lyme Prevention Trial Nears,” Acadia Healthcare (ACHC) is linked, with no stored direction, medium confidence. Reason on file: GA selected ACHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- ASND Ascendis Pharma A/S
For “Tonix Pharmaceuticals Targets TONMYA Growth as Lyme Prevention Trial Nears,” Ascendis Pharma A/S (ASND) is linked, with no stored direction, medium confidence. Reason on file: GA selected ASND as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- ATYR aTYR PHARMA
In “Tonix Pharmaceuticals Targets TONMYA Growth as Lyme Prevention Trial Nears,” aTYR PHARMA (ATYR) is linked, with no stored direction, medium confidence. Reason on file: GA selected ATYR as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- BBIO BridgeBio Pharma
BridgeBio Pharma (BBIO) is linked, with no stored direction, medium confidence in the 13 Sep 2026 story “Tonix Pharmaceuticals Targets TONMYA Growth as Lyme Prevention Trial Nears.” Reason on file: GA selected BBIO as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- DVA Davita
In “Tonix Pharmaceuticals Targets TONMYA Growth as Lyme Prevention Trial Nears,” Davita (DVA) is linked, with no stored direction, medium confidence. Reason on file: GA selected DVA as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- GEHC GE HealthCare Technologies
GE HealthCare Technologies (GEHC) is linked, with no stored direction, medium confidence in the 13 Sep 2026 story “Tonix Pharmaceuticals Targets TONMYA Growth as Lyme Prevention Trial Nears.” Reason on file: GA selected GEHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
Acadia Healthcare (ACHC)
Acadia Healthcare (ACHC) is the company in “Tonix Pharmaceuticals Targets TONMYA Growth as Lyme Prevention Trial Nears,” the 13 Sep 2026 this story story.
What ties Acadia Healthcare (ACHC) to the headline is this: GA selected ACHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
A second company, Ascendis Pharma A/S (ASND), is listed for a different reason: GA selected ASND as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
Dates and price levels for Acadia Healthcare (ACHC)
ACHC traded between 26.75 and 32.03 across 20 sessions. The latest close on file is 30.20. ASND traded between 219.69 and 240.84 across 20 sessions. The latest close on file is 229.99. ATYR traded between 0.17 and 0.41 across 20 sessions. The latest close on file is 0.17.
A simple score for Acadia Healthcare (ACHC)
46 out of 100
“Tonix Pharmaceuticals Targets TONMYA Growth as Lyme Prevention Trial Nears” scores 46 out of 100. The score uses 1 sources, and 6 linked companies.